title: Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
abstract: Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.
authors.affiliation: Department of Dermatology, Ghent University Hospital,Gent, Belgium. reinhart.Speeckaert@ugent.be.
authors.forename: R
authors.initials: R
authors.lastname: Speeckaert
authors.affiliation: Department of Dermatology, Ghent University Hospital,Gent, Belgium.
authors.forename: N
authors.initials: N
authors.lastname: van Geel
authors.affiliation: Department of Dermatology, Ghent University Hospital,Gent, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Lambert
authors.affiliation: Department of Nephrology, Ghent University Hospital,Gent, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Claeys
authors.affiliation: Department of Clinical Chemistry, Ghent University Hospital,Gent, Belgium.
authors.forename: J R
authors.initials: JR
authors.lastname: Delanghe
authors.affiliation: Department of Nephrology, Ghent University Hospital,Gent, Belgium.
authors.forename: M M
authors.initials: MM
authors.lastname: Speeckaert
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508717:IL17A protein, human; D020381:Interleukin-17; C555450:secukinumab
keywords: IL-17A; Monoclonal antibodies; Psoriasis; Psoriatic arthritis; Secukinumab; bDMARDs